Research Article
Taurine Ameliorates Iron Overload-Induced Hepatocyte Injury via the Bcl-2/VDAC1-Mediated Mitochondrial Apoptosis Pathway

Xiaoyu Feng,1 Wenfeng Hu,1,2 Yujiao Hong,1 Linlin Ruan,1 Yueben Hu,1 and Dan Liu1

1Jiangxi Provincial Key Laboratory of Basic Pharmacology, Nanchang University School of Pharmaceutical Science, Nanchang 330006, China
2Department of Pharmacy, Jiujiang Traditional Chinese Medicine Hospital, Jiujiang 332900, China

Correspondence should be addressed to Dan Liu; liudan1201jx@163.com

Received 6 December 2021; Revised 20 May 2022; Accepted 31 May 2022; Published 16 July 2022

Academic Editor: Zhihao Jia

Copyright © 2022 Xiaoyu Feng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Iron overload can induce reactive oxygen species (ROS) burst and liver damage. Taurine can reduce ROS production and ameliorate liver injury caused by iron overload; however, the underlying molecular mechanism remains elusive. Herein, L02 cells treated with 120 μM iron dextran for 48 h showed marked oxidative stress damage and significantly increased apoptosis. Taurine protected hepatocytes by stabilizing mitochondrial membranes and resisting oxidative stress damage caused by iron overload. However, transfection with siRNA Bcl-2 virus abrogated the observed protective effects. Following treatment with taurine, B cell lymphoma-2 (Bcl-2) could inhibit the opening of the mitochondrial permeability transition pore (mPTP), subsequently stabilizing the mitochondrial membrane potential by interacting with voltage-dependent anion channel 1 (VDAC1) of mPTP. The present study is the first to clarify the mechanism underlying taurine-aided hepatocyte protection against iron overload-induced oxidative stress via Bcl-2-mediated inhibition of mPTP opening and the antiapoptotic pathway.

1. Introduction

Given changing eating habits and dietary structure, iron cooking utensils are widely employed, and large amounts of red meat (including heme iron), iron-fortified foods, and iron supplements are often abused [1]. Both researchers and clinical investigators have reported that excess or misplaced iron in specific tissues and cells can promote a vast array of acute and chronic illnesses [2]. The liver is the most likely organ to accumulate iron [3], and long-term liver iron overload is highly correlated with the occurrence, development, and prognosis of hepatitis, liver fibrosis, cirrhosis, and tumors. The ability of iron to exchange single electrons with several substrates can induce reactive oxygen species (ROS) generation [4–6], which, in turn, can lead to oxidative stress, lipid peroxidation, and DNA damage, inducing genomic instability and DNA repair defects [7, 8], ultimately impairing cell viability and promoting programmed cell death (PCD) [9]. Mitochondria, one of the sources of signals that initiate apoptosis, play a key role in apoptotic cell death [10]. It is well-known that mitochondrial permeability transition pore (mPTP) opening plays an important role in mitochondria-mediated apoptosis [11]. The opening of mPTP can also result in mitochondrial swelling, mitochondrial membrane damage, and subsequent release of cytochrome c which are hallmarks of mitochondrial-mediated apoptosis [12].

Taurine is a sulfur-containing amino acid. Studies have shown that taurine is involved in the maintenance and regulation of nearly all normal physiological activities in the body, as well as mediates important inhibitory and protective effects against several pathological conditions [13–15]. Altered taurine expression can reportedly impact physiological processes such as development, lung function, mitochondrial and cartilage function, antioxidation, and apoptosis [16]. Studies have found that taurine can reduce heavy metal-induced toxic liver damage and highlighted that taurine is a good dietary antioxidant [17]. Previously, we have reported that taurine supplementation can reduce liver oxidative stress and damage, protecting liver function and improving survival in an iron-overloaded murine model [18]. Therefore, we aimed to verify the underlying...
mechanism through which iron overload causes oxidative stress and excessive apoptosis in liver cells. Using taurine as a therapeutic agent, we examined the mechanism underlying its protective effect against iron overload-induced liver injury, especially oxidative stress and mitochondrial pathway-mediated apoptosis.

2. Method

2.1. Materials. Taurine (purity ≥99.0%) was purchased from Beijing Solarbio Science & Technology Co. (Beijing, China), Ltd., and iron dextran was purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Lentivirus siRNA Bcl-2 and a negative control virus were constructed by GeneChem Co. (Shanghai, China). Protein G Plus/Protein A Agarose was purchased from Merck Millipore (USA). Antibodies against Bcl-2, COX-4, and cytochrome c (Cyt c) were purchased from Cell Signaling Technology (Beverly, MA, USA), while the antibody against voltage-dependent anion channel 1 (VDAC1) was purchased from Santa Cruz Biotechnology (USA). Antibodies against β-actin and horseradish peroxidase-conjugated IgG secondary antibodies were obtained from ZsBio (Beijing, China). L02 cells were derived from normal human hepatocytes and provided by Prof. Zhinjun Luo (Nanchang University). L02 cells were cultured in DMEM/F12 (Gibco, South America) supplemented with 10% fetal bovine serum (Gibco, South America) and antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin; Solarbio, Beijing, China) at 37°C in a 5% CO₂ incubator.

2.2. Experimental Groups. Herein, we constructed an iron overload injury model by treating cells with 120 μM iron dextran for 48 h. Five cell groups were established: control group, L02 cells cultured under normal conditions; iron overload group, cells cultured with 120 μM iron dextran and 40 mM taurine for 48 h; iron+taurine group, cells treated with 120 μM iron dextran and 40 mM taurine for 48 h; iron+taurine-negative control virus group, cells infected with Bcl-2 unloaded lentivirus negative control for 10 h before the iron overload injury model was constructed; iron+taurine+siRNA Bcl-2 group, infected with Bcl-2 knockdown virus for 10 h before the iron overload injury model was constructed. All experiments were performed in triplicate.

2.3. Cell Viability. Cell viability was detected using the CCK-8 kit (Apexbio, USA). Briefly, cells were seeded in 96-well plates. After treatment, cells were washed with phosphate-buffered saline (PBS; Solarbio, Beijing, China), and 90 μL serum-free medium and 10 μL CCK-8 reagent were added to each well and mixed evenly. Cells were then incubated at 37°C in a 5% CO₂ incubator for 2 h in the dark. Absorbance was measured at 450 nm using an enzyme labeling instrument (Bio-Rad 680, USA). The optical density (OD) was directly proportional to the cell survival rate, and the cell survival rate was calculated according to the formula.

2.4. Apoptosis. Annexin V-FITC and propidium iodide (PI) (BestBio, Shanghai, China) double staining were used to examine apoptosis. After treatment, cells were digested with trypsin without EDTA (Solarbio, Beijing, China), and the supernatant was subsequently removed. Then, cells were resuspended in 500 μL annexin binding solution, and 5 μL of annexin V-FITC dye was added to cells in the dark. After incubation at 4°C in the dark for 15 min, 10 μL PI dye was added and mixed well, followed by incubation at 4°C in the dark for another 5 min. Flow cytometry detection was performed at an excitation wavelength of 488 nm and emission wavelength of 525 nm (Cytomics FC 500, Beckman Kurt, Brea, CA, USA).

2.5. ROS. A reactive oxygen kit was used to detect ROS levels in cells. 2',7'-Dichlorodihydrofluorescein diacetate (DCFH-DA) (Beyotime Biotechnology, Shanghai, China) was used as the probe. Cells from each experimental group were collected in Eppendorf tubes. The probes were prepared in serum-free medium with DCFH-DA at a ratio of 1000:1. Then, 500 μL of the prepared solution was added to each tube, incubated at 37°C in a 5% CO₂ incubator for 20 min in the dark, washed twice with PBS, and analyzed by flow cytometry.

2.6. Degree of mPTP Opening. Mitochondrial swelling fluid and CaCl₂ solution were prepared, and the intracellular mitochondria in each group were separated using a mitochondrial extraction kit (Keygenbio, Nanjing, China). Briefly, 160 μL of mitochondrial swelling fluid was added, and the mixture was resuspended in a microplate reader at 520 nm to detect the absorbance value of each group OD. Then, 40 μL CaCl₂ solution was added to each experimental group and detected every minute, calculated as ΔOD/min = (OD₁−OD₂) ×1000 to indicate the degree of mPTP opening.

2.7. Western Blot Analysis. Cells from each experimental group were collected, and lysates were prepared using RIPA : PMSF (100 : 1; Beyotime Biotechnology, Shanghai, China and Solarbio, Beijing, China, respectively); cells were lysed at 4°C for 20 min. Next, cells were centrifuged at 4°C for 15 min at 12000 rpm/min. Subsequently, cells were separated from the supernatant and used to determine the protein concentration with the BCA kit (Tiangen Biology, Beijing, China). Protein (30 μg) was loaded on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a gel apparatus (Bio-Rad, USA) and separated, followed by transfer to polyvinylidene fluoride (PVDF) membranes (Millipore Corp., Bedford, MA, USA) at 90 mA, 0°C wet for 1.5 h. The membrane was blocked for 2 h with 5% skim milk at room temperature. Bcl-2, VDAC1, the membrane of β-actin protein, and its primary antibody (1 : 1000 dilution) were incubated overnight at 4°C. After 24 h, the membrane was washed with 1× TBST (Tris-Buffer Saline, 0.25% Tween-20) for 10 min (×5 times), incubated with the horseradish peroxidase-conjugated secondary antibody (1:2000 dilution) for 1.5 h at room temperature, and washed with TBST for 10 min (×4 times). After coating the wetting film with an enhanced chemiluminescence reagent (ECL kit,
Thermo Fisher Scientific, USA), the protein was developed using the Image Laboratory System (Bio-Rad, USA).

Mitochondrial and cytoplasmic proteins were extracted using the mitochondrial extraction kit for each experimental group, and the protein concentration was determined using the BCA method. After separation by SDS-PAGE, proteins were transferred to a PVDF membrane and blocked for 2 h. The primary antibody was combined with COX-4 and Cyt c proteins and incubated overnight at 4°C. After 24 h, cells were washed five times and incubated with a secondary antibody at room temperature for 2 h. The membrane was then moistened with the chemiluminescence solution.

2.8. Coimmunoprecipitation. Briefly, a measured concentration of the protein extracted was combined with the indicated primary antibodies and incubated overnight at 4°C. After 24 h, the Protein G Plus/Protein A Agarose was washed twice, and agarose was mixed and incubated with the protein and its primary antibody overnight. After 24 h, cells were thrice washed with PBS. The supernatant was removed, and protein loading buffer was added to the precipitate and heated for 10 min at 100°C. The samples were analyzed by SDS-PAGE.

2.9. Oxidative Stress and Lipid Peroxidation. It is well known that ROS generation can cause oxidative stress, and the formation of lipid peroxides can induce cell damage. Superoxide dismutase (SOD) is the most commonly used indicator of oxidative stress, and malondialdehyde (MDA) is an indicator of the degree of lipid peroxidation. Brieﬂy, oxidative stress, and MDA is an indicator of the degree of lipid peroxidation. For each experimental group, data were detected according to the instructions of the iron ion detection kit (APPLYGEN, Beijing, China). The concentration of iron ions in each group was determined by measuring the absorbance value using the speciﬁc kit. Compared with the control group, the concentration of iron ions was signiﬁcantly increased in the iron overload group when compared with the control group. Treatment with 40 mM taurine signiﬁcantly decreased apoptosis. The optimal concentration of taurine was determined to be 40 mM. In addition, apoptosis was signiﬁcantly reduced in the iron+taurine and iron+taurine+NC groups but was signiﬁcantly elevated in siRNA Bcl-2 cells, suggesting that the protective effect of taurine was abolished. These results indicated that taurine could exert antiapoptotic effects through Bcl-2.

Moreover, taurine did not signiﬁcantly impact the cellular concentration of iron ions. The concentration of iron ions in each group was determined by measuring the absorbance value using the speciﬁc kit. Compared with the control group, the concentration of iron ions was signiﬁcantly elevated in the other groups (Figure 2(d)). The results revealed that taurine did not signiﬁcantly alter the intracellular iron concentration.

3. Results

3.1. Effect of Taurine Treatment on Iron Overload Damage. First, L02 cells were treated with media containing different concentrations of iron dextran for 48 h. L02 cells were treated with 0, 10, 20, 40, 80, 120, 160, 200, and 240 μM iron dextran for 48 h. The half-maximal inhibitory concentration of dextran was 128.4 μM (Figure 1(a)). Iron dextran (120 μM)-treated L02 cells were then treated with taurine at concentrations of 10, 20, 40, 50, 60, 80, and 100 mM, and 40 mM was found to be an optimal concentration to afford protection (Figure 1(b)).

We observed that treatment with 120 μM iron dextran decreased cell viability. Taurine could reverse this effect, and we observed that L02 cell viability was signiﬁcantly restored by 40 mM taurine (Figure 1(c)). As determined by ﬂow cytometry, the apoptosis results further conﬁrmed that taurine inhibited iron dextran-induced apoptosis (Figure 1(d)). Based on these ﬁndings, L02 cells incubated with 120 μM iron dextran and 40 mM taurine were used in subsequent experiments.

3.2. Role of Bcl-2 in Taurine-Mediated Protective Effects against Iron Overload Injury. The protective effect of taurine against iron overload could be associated with Bcl-2 expression level. Taurine exhibited a protective effect against iron overload-induced cell damage (Figure 2). Western blotting revealed that taurine increased the Bcl-2 protein level (Figure 2(a)). Accordingly, we constructed a Bcl-2 knockdown virus (Figure 2(b)). CKC-8 results showed that taurine improved cell viability (Figure 2(c)). Bcl-2 gene knockdown using a Bcl-2 knockdown virus abrogated the protective effects of taurine.

Furthermore, we observed that taurine could reduce the apoptosis rate. Flow cytometry was used to determine the rate of apoptosis (Figure 2(e)). Apoptosis was signiﬁcantly increased in the iron overload group when compared with the control group. Treatment with 40 mM taurine signiﬁcantly decreased apoptosis. The optimal concentration of taurine was determined to be 40 mM. In addition, apoptosis was signiﬁcantly reduced in the iron+taurine and iron+taurine+NC groups but was signiﬁcantly elevated in siRNA Bcl-2 cells, suggesting that the protective effect of taurine was abolished. These results indicated that taurine could exert antiapoptotic effects through Bcl-2.

Moreover, taurine did not signiﬁcantly impact the cellular concentration of iron ions. The concentration of iron ions in each group was determined by measuring the absorbance value using the speciﬁc kit. Compared with the control group, the concentration of iron ions was signiﬁcantly elevated in the other groups (Figure 2(d)). The results revealed that taurine did not signiﬁcantly alter the intracellular iron concentration.

3.3. Impact of Bcl-2 and VDAC1 Interaction on the Anti-Iron Overload Injury Mediated by Taurine. The effect of taurine on Bcl-2 and VDAC1 protein level was examined using western blotting. Bcl-2 protein level was signiﬁcantly higher in the iron+taurine and iron+taurine+NC groups than in the control group (Figure 3(a)). Taurine treatment decreased the expression level of VDAC1 when compared with that in the control group. Following Bcl-2 gene knockdown, the level of Bcl-2 protein decreased, and VDAC1 level was also signiﬁcantly reduced, suggesting that the level of VDAC1 may be related to Bcl-2.

Previous studies have shown that Bcl-2 interacts with VDAC1, and taurine can increase Bcl-2 protein level. We postulated that the protective effect of taurine might be...
Figure 1: Continued.
related to the interaction between Bcl-2 and VDAC1. To further confirm this hypothesis, the interaction between Bcl-2 and VDAC1 was examined using coimmunoprecipitation (Co-IP) after taurine treatment. The results revealed that under normal conditions (control group), Bcl-2 interacted with VDAC1 (Figure 3(d)). After taurine treatment, the interaction between Bcl-2 and VDAC1 was enhanced. On infecting L02 cells with siRNA Bcl-2 lentivirus, Bcl-2 was knocked out, the observed effects were reversed, and the interaction between Bcl-2 and VDAC1 decreased. As shown in Figure 3, taurine pretreatment could promote the interaction between Bcl-2 and VDAC1. Additionally, the above findings revealed that VDAC1 activation might be associated with Bcl-2 upregulation, suggesting that taurine combats iron overload damage and that this effect could be related to the interaction between Bcl-2 and VDAC1.

3.4. Effect of Taurine on Cell Lipid Peroxidation. Taurine can reduce ROS levels in iron overload-damaged cells. The cellular ROS levels were measured by flow cytometry.
Figure 2: Continued.
Compared with the control group, the ROS level was significantly increased in the iron overload group, while those in the iron+taurine and iron+taurine+NC groups were significantly decreased. Accordingly, it can be suggested that taurine reduces intracellular ROS levels. Bcl-2 gene knockdown abolished the taurine-mediated effects.

SOD indicates the ability of cells to scavenge oxygen free radicals, whereas MDA indicates the severity of cells being attacked by free radicals; both these indicators can indirectly reflect the degree of cell damage. Iron overload decreased the SOD activity and increased the MDA content in cells. Taurine treatment significantly enhanced SOD activity and reduced MDA content (Figures 4(c) and 4(d)). However, following Bcl-2 knockdown, these taurine-mediated effects were reversed, suggesting that taurine treatment could reduce the degree of lipid peroxidation in cells via Bcl-2, thereby reducing damage.
Figure 3: (a) Western blot analysis was performed to examine the expression level of Bcl-2 and VDAC1 in L02 cells. (b) Bcl-2 protein level in L02 cells. (c) VDAC1 protein level in L02 cells. (d) Coimmunoprecipitation was used to study the interaction between Bcl-2 and VDAC1 in different experimental groups. Data values are expressed as mean ± standard error of the mean (SEM), n = 3. *P < 0.05 vs. the control group. **P < 0.01 vs. the control group. #P < 0.05 vs. the iron group. &&P < 0.01 vs. the iron group.
Figure 4: Continued.
3.5. Taurine Protected Mitochondrial Membrane Integrity.
We observed that taurine treatment could reduce the degree of mPTP opening (Figures 5(a) and 5(b)). A microplate reader was used to measure the absorbance of each group to determine the degree of mPTP opening, calculated as ΔOD/min × 1000. Compared with the control group, the degree of mPTP opening increased in iron-treated cells. The degree of mPTP opening decreased in the iron+taurine and iron+taurine+NC groups. In cells infected with siRNA Bcl-2 lentivirus for Bcl-2 knockdown, the degree of mPTP opening continued increasing despite taurine treatment, suggesting that the protective effect of taurine was abolished.

Treatment with taurine blocked Cyt c transfer from the mitochondria to the cytoplasm. Western blotting was used to detect the protein level of Cyt c, an indicator of cell apoptosis, in the mitochondria and cytoplasm. Compared with the control group, iron overload induced Cyt c accumulation in the cytoplasm, with minimal accumulation observed in the mitochondria (Figures 5(c) and 5(d)). In the taurine treatment group, Cyt c accumulated in the mitochondria and decreased in the cytoplasm. The taurine-mediated effect was abolished in the iron+taurine+siRNA Bcl-2 group, suggesting that taurine could protect L02 cells from iron overload damage via Bcl-2, inhibit the transfer of Cyt c from the mitochondria to the cytoplasm, and maintain mitochondrial membrane integrity.

4. Discussion
Iron is an essential micronutrient for most organisms, well known to be involved in growth and metabolism, erythrocyte production, oxygen transport, DNA synthesis, and cellular immune response [19, 20]. However, excessive iron poses a substantial health risk during several diseases. Iron is stored and accumulates in the liver. It is most likely to cause iron damage to the liver, eventually resulting in liver fibrosis, cirrhosis, and even liver cancer. Iron can participate in redox reactions, causing oxidative stress and generating substantial ROS generation. Mitochondria are not only a source but also a target of ROS [21]. Disruption of mitochondrial dynamics produce increased levels of ROS [22]. Using the oxidant-sensing probe DCFH-DA to measure ROS levels, we found that hepatocytes treated by iron overload accumulated more ROS than hepatocytes without iron treatment. The high levels of ROS contribute directly to oxidative stress. SOD and MDA are commonly used biomarkers for oxidative stress [23]. By measuring SOD activity and MDA content, it was revealed that iron overload led to significantly increased MDA levels and decreased SOD levels, suggesting increased oxidative stress in hepatocytes.

Taurine is an endogenously synthesized sulfur-containing β-amino acid found in mammals and is derived from methionine and cysteine. It participates in diverse physiological functions. For example, it is involved in modulating osmotic pressure and calcium regulation and plays a major role in maintaining membrane stability and immune regulation [24–26]. Taurine also exhibits a variety of physiological activities, including anti-inflammatory, antioxidant, and antiapoptotic activities. In the present study, CCK-8 and apoptosis tests showed that the application of 120 μM iron dextran for 48 h damaged hepatocytes. Treatment with an effective dose of taurine restored liver cell viability and alleviated apoptosis.

Bcl-2 family proteins include Bcl-2, B cell lymphoma-extra large (Bcl-xL), and Bcl-2-associated X (Bax). Bcl-2...
Figure 5: Continued.
family proteins are considered one of the main regulators of apoptosis [27]. Studies have also shown that members of the Bcl-2 family are new types of intracellular calcium (Ca\(^{2+}\)) regulators. Most apoptotic pathways occur in the cell mitochondria, and the permeability changes in the mitochondrial membrane are closely related to the Bcl-2 protein [28–30]. Therefore, we speculated that taurine could suppress iron overload-induced cell damage, reduce cell apoptosis, and improve cell survival, potentially via the Bcl-2 protein. Western blotting revealed that taurine upregulated Bcl-2 protein level. We used siRNA Bcl-2 lentiviral to knock out the Bcl-2 protein and observed that the protective effect of taurine was abolished. These results indicated that the protective effect of taurine could be related to Bcl-2. Several studies have shown that the Bcl-2 family can participate in the formation of lipid membrane ion channels [31, 32], and alterations in cell membrane permeability play a key role in apoptosis [33, 34]. And mPTP is a multiprotein complex pore composed of mitochondrial voltage-dependent anion channel 1 (VDAC1), adenylate transferase (ANT) in the
inner membrane, and cyclophilin (CyP-D) in the substrate [35, 36]. Recent studies have shown that outer membrane channels, such as the mitochondrial apoptosis-inducing channel and VDAC, are directly or indirectly involved in regulating mitochondrial permeability during apoptosis and necrosis [37–39]. Therefore, we postulated that the change in the mPTP might be related to VDAC1 [40]. In addition, Bcl-2 regulates the permeability of mitochondria from many aspects and plays an important role in mitochondrial-mediated apoptosis. Bcl-2 directly modulates cellular energy metabolism by regulating the respiratory chain [41]. Bcl-2 can bind to ion channels to regulate the release of Cyt c [42]. Bcl-2 can bind to VDAC1 to interact, shut down mPTP, and maintain the integrity of mitochondrial membranes [43]. In the present study, following the knockdown of Bcl-2, the level of VDAC1 was also significantly downregulated. It has been speculated that Bcl-2 may be related to VDAC1. Therefore, we speculated that Bcl-2 acts on VDAC1 to exert antiapoptotic effects. Co-IP experiments were used to detect the interaction between Bcl-2 and VDAC1 in liver cells. We observed that the interaction between Bcl-2 and VDAC1 was more potent in the taurine-administered group than in the control group. These results suggest that the protective effect of taurine may be mediated via the interaction between Bcl-2 and VDAC1.

In the present study, taurine did not impact the iron concentration in hepatocytes damaged by excessive iron overload. Interestingly, taurine exhibited a significant protective effect on hepatocytes damaged by iron overload. Our results showed that taurine induced the protein level of Bcl-2 and turned off mPTP, thereby inhibiting the ROS burst and maintaining mitochondrial membrane integrity by preventing the release of Cyt c from the mitochondria to the cytoplasm. Therefore, it is essential to detect the degree of mPTP opening. The prolonged opening of the mPTP causes swelling of organelles and mitochondrial depolarization, eventually leading to the rupture of the outer mitochondrial membrane, and the material in the interstitial space is released into the cytoplasm. Studies have found that mPTP is not only related to the rupture of the outer mitochondrial membrane during apoptosis but is also associated with a variety of pathologies [44, 45]. If mPTP is opened for a prolonged period, mitochondria release a considerable amount of Cyt c and apoptosis-inducing factors into the cytoplasm after rupture of the outer membrane. Compared with the iron overload group, taurine reduced the opening of the mPTP, decreased ROS burst, and inhibited Cyt c from the mitochondria to the cytoplasm. Following the knockdown of Bcl-2 protein, the protective effect of taurine was abolished, along with an increased degree of mPTP opening, elevated ROS burst, and enhanced Cyt c accumulated in the cytoplasm.

5. Conclusion

In summary, taurine inhibited hepatocyte apoptosis primarily via regulation of the mitochondrial-dependent pathway. Taurine was found to upregulate Bcl-2 protein level, enhance the interaction between Bcl-2 and VDAC1, reduce the opening of the mPTP, inhibit ROS burst, and inhibit the transfer of Cyt c from the mitochondria to the cytoplasm to maintain mitochondrial membrane integrity, thereby inhibiting hepatocyte apoptosis.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors report no conflicts of interests.

Authors’ Contributions

Xiaoyu Feng and Wenfeng Hu contributed equally to this work.

Acknowledgments

This work was supported by the Natural Science Foundation of China (Nos. 81460551, 81760587, 81460371, and 81760731), the Graduate Student Innovation Special Foundation of Nanchang University (No. cx2016299), and the Jiangxi Province Technology Support and Social Development Projects (No. 2010BSA13900).

References

[1] C. Geissler and M. Singh, “Iron, meat and health,” Nutrients, vol. 3, no. 3, pp. 283–316, 2011.
[2] E. D. Weinberg, “The hazards of iron loading,” Metallomics, vol. 2, no. 11, pp. 732–740, 2010.
[3] E. R. Anderson and Y. M. Shah, “Iron homeostasis in the liver,” Comprehensive Physiology, vol. 3, no. 1, pp. 315–330, 2013.
[4] H. M. Moukhadder, R. Halawi, M. D. Cappellini, and A. T. Taher, “Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: a comprehensive review,” Cancer, vol. 123, no. 5, pp. 751–758, 2017.
[5] L. J. Britton, V. N. Subramaniam, and D. H. Crawford, “Iron and non-alcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 22, no. 36, pp. 8112–8122, 2016.
[6] A. Fonseca-Nunes, P. Jakszyn, and A. Agudo, “Iron and cancer risk—a systematic review and meta-analysis of the epidemiological evidence,” Cancer Epidemiology, Biomarkers & Prevention, vol. 23, no. 1, pp. 12–31, 2014.
[7] C. Zhang, “Essential functions of iron-requiring proteins in DNA replication, repair and cell cycle control,” Protein & Cell, vol. 5, no. 10, pp. 750–760, 2014.
[8] V. D. Paul and R. Lill, “Biogenesis of cytosolic and nuclear iron-sulfur proteins and their role in genome stability,” Biochimica et Biophysica Acta, vol. 1853, no. 6, pp. 1528–1539, 2015.
[9] R. Gozzelino and P. Arosio, “The importance of iron in pathophysiological conditions,” Frontiers in Pharmacology, vol. 6, p. 26, 2015.
[10] W. Zeng, X. Wang, P. Xu, G. Liu, H. S. Eden, and X. Chen, “Molecular imaging of apoptosis: from micro to macro,” Theranostics, vol. 5, no. 6, pp. 559–582, 2015.
[11] M. P. Mattson and T. V. Arumugam, “Hallmarks of brain aging: adaptive and pathological modification by metabolic states,” Cell Metabolism, vol. 27, no. 6, pp. 1176–1199, 2018.
[12] C. E. Paulsen and K. S. Carroll, “Cysteine-mediated redox signaling: chemistry, biology, and tools for discovery,” Chemical Reviews, vol. 113, no. 7, pp. 4633–4679, 2013.

[13] W. Chen, J. Guo, Y. Zhang, and J. Zhang, “The beneficial effects of taurine in preventing metabolic syndrome,” Food & Function, vol. 7, no. 4, pp. 1849–1863, 2016.

[14] S. Murakami, “Role of taurine in the pathogenesis of obesity,” Molecular Nutrition & Food Research, vol. 59, no. 7, pp. 1353–1363, 2015.

[15] C. J. Jong, T. Ito, H. Prentice, J. Y. Wu, and S. W. Schaffer, “Role of mitochondria and endoplasmic reticulum in taurine-deficiency-mediated apoptosis,” Nutrients, vol. 9, no. 8, p. 795, 2017.

[16] J. J. Caine and T. D. Geracioti, “Taurine, energy drinks, and neuroendocrine effects,” Cleveland Clinic Journal of Medicine, vol. 83, no. 12, pp. 895–904, 2016.

[17] Z. Zhang, D. Liu, B. Yi et al., “Taurine supplementation reduces oxidative stress and protects the liver in an iron-overload murine model,” Molecular Medicine Reports, vol. 10, no. 5, pp. 2255–2262, 2014.

[18] T. Zhao, Z. Xia, and F. Wang, “Zebrashift in the sea of mineral (iron, zinc, and copper) metabolism,” Frontiers in Pharmacology, vol. 5, p. 33, 2014.

[19] O. Loréal, T. Cavey, E. Bardou-Jacquet, P. Guggenbuhl, M. Ropert, and P. Brissot, “Iron, hepcidin, and the metal connection,” Frontiers in Pharmacology, vol. 5, p. 128, 2014.

[20] D. Liu, H. He, D. Yin et al., “Mechanism of chronic dietary iron overload-induced liver damage in mice,” Molecular Medicine Reports, vol. 7, no. 4, pp. 1173–1179, 2013.

[21] B. Niemann, S. Rohrbach, M. R. Miller, D. E. Newby, V. Fuster, and J. C. Kovacic, “Oxidative stress and cardiovascular risk: obesity, diabetes, smoking, and pollution: part 3 of a 3-part series,” Journal of the American College of Cardiology, vol. 70, no. 2, pp. 230–251, 2017.

[22] B. Han, Z. Lv, X. Han et al., “Harmful effects of inorganic mercury exposure on kidney cells: mitochondrial dynamics disorder and excessive oxidative stress,” Biological Trace Element Research, vol. 200, no. 4, pp. 1591–1597, 2022.

[23] J. Li, Z. Yu, B. Han et al., “Activation of the GPX4/TLR4 signaling pathway participates in the alleviation of selenium yeast on neuroendocrine effects,” Journal of Bioenergetics and Biomembranes, vol. 59, no. 5, pp. 2946–2961, 2022.

[24] B. S. Kendler, “Taurine: an overview of its role in preventive medicine,” Preventive Medicine, vol. 18, no. 1, pp. 79–100, 1989.

[25] H. L. Han, J. F. Zhang, E. F. Yan et al., “Effects of taurine on growth performance, antioxidant capacity, and lipid metabolism in broiler chickens,” Poultry Science, vol. 99, no. 11, pp. 5707–5717, 2020.

[26] S. Murakami, A. Ono, A. Kawasaki, T. Takenaga, and T. Ito, “Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro,” Amino Acids, vol. 50, no. 9, pp. 1279–1288, 2018.

[27] J. L. Morris, G. Gillet, J. Prudent, and N. Popgeorgiev, “Bcl-2 family of proteins in the control of mitochondrial calcium signalling: an old chap with new roles,” International Journal of Molecular Sciences, vol. 22, no. 7, p. 3730, 2021.

[28] Y. Tsujimoto and C. M. Croce, “Analysis of the structure, transcripts, and protein products of Bcl-2, the gene involved in human follicular lymphoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 14, pp. 5214–5218, 1986.

[29] A. R. Delbridge, S. Grabow, A. Strasser, and D. L. Vaux, “Thirty years of Bcl-2: translating cell death discoveries into novel cancer therapies,” Nature Reviews Cancer, vol. 16, no. 2, pp. 99–109, 2016.

[30] R. J. Youle and A. Strasser, “The Bcl-2 protein family: opposing activities that mediate cell death,” Nature Reviews. Molecular Cell Biology, vol. 9, no. 1, pp. 47–59, 2008.

[31] B. Antonsson, F. Conti, A. Ciavatta et al., “Inhibition of Bax channel-forming activity by Bcl-2,” Science, vol. 277, no. 5324, pp. 370–372, 1997.

[32] S. L. Schendel, R. Azimov, K. Pawlowski, A. Godzik, B. L. Kagan, and J. C. Reed, “Ion channel activity of the BH3 only Bcl-2 family member, BID*,” The Journal of Biological Chemistry, vol. 274, no. 31, pp. 21932–21936, 1999.

[33] S. Grimm and D. Brdiczka, “The permeability transition pore in cell death,” Apoptosis, vol. 12, no. 5, pp. 841–855, 2007.

[34] A. Rasola and P. Bernardi, “The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis,” Apoptosis, vol. 12, no. 5, pp. 815–833, 2007.

[35] J. N. Weiss, P. Korge, H. M. Honda, and P. Ping, “Role of the mitochondrial permeability transition in myocardial disease,” Circulation Research, vol. 93, no. 4, pp. 292–301, 2003.

[36] K. W. Kinnally, P. M. Peixoto, S. Y. Ryu, and L. M. Dejan, “Is mPTP the gatekeeper for necrosis, apoptosis, or both?,” Biochimica et Biophysica Acta, vol. 1813, no. 4, pp. 616–622, 2011.

[37] L. M. Dejan, S. Martinez-Caballero, and K. W. Kinnally, “Is MAC the knife that cuts cytochrome c from mitochondria during apoptosis?,” Cell Death and Differentiation, vol. 13, no. 8, pp. 1387–1395, 2006.

[38] L. M. Dejan, S. Martinez-Caballero, S. Manon, and K. W. Kinnally, “Regulation of the mitochondrial apoptosis-induced channel, MAC, by Bcl-2 family proteins,” Biochimica et Biophysica Acta, vol. 1762, no. 2, pp. 191–201, 2006.

[39] T. K. Rostovtsева, W. Tan, and M. Colombini, “On the role of VDAC in apoptosis: fact and fiction,” Journal of Bioenergetics and Biomembranes, vol. 37, no. 3, pp. 129–142, 2005.

[40] V. Shoshan-Barmatz, V. De Pinto, M. Zweckstetter, Z. Raviv, N. Keinan, and N. Arbel, “VDAC, a multi-functional mitochondrial protein regulating cell life and death,” Molecular Aspects of Medicine, vol. 31, no. 3, pp. 227–285, 2010.

[41] G. Benard, N. Bellance, C. Jose, S. Melser, K. Noutette-Gaulain, and R. Rossignol, “Multi-site control and regulation of mitochondrial energy production,” Biochimica et Biophysica Acta, vol. 1797, no. 6-7, pp. 698–709, 2010.

[42] H. Zhang, Q. Li, Z. Li, Y. Mei, and Y. Guo, “The protection of Bcl-2 overexpression on rat cortical neuronal injury caused by analogous ischemia/reperfusion in vitro,” Neuroscience Research, vol. 62, no. 2, pp. 140–146, 2008.

[43] N. Arbel and V. Shoshan-Barmatz, “Voltage-dependent anion channel 1-based peptides interact with Bcl-2 to prevent apoptotic activity,” The Journal of Biological Chemistry, vol. 285, no. 9, pp. 6053–6062, 2010.

[44] P. Singh, S. Suman, S. Chandna, and T. K. Das, “Possible role of amyloid-beta, adenine nucleotide translocase and cyclophilin-D interaction in mitochondrial dysfunction of Alzheimer’s disease,” Bioinformation, vol. 3, no. 10, pp. 440–445, 2009.

[45] K. G. Su, G. Banker, D. Bourdette, and M. Forte, “Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis,” Current Neurology and Neuroscience Reports, vol. 9, no. 5, pp. 411–417, 2009.